Unlock instant, AI-driven research and patent intelligence for your innovation.

Lactate-protected hypoglycemia to treat glycolysis dependent pathological conditions, in particular cancer

A dependent, glycolytic technology, applied in the direction of resistance to vector-borne diseases, organic active ingredients, medical preparations containing active ingredients, etc.

Pending Publication Date: 2021-06-08
LACA MEDICAL BV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

These side effects are unacceptable, making sodium lactate unsuitable for inducing persistent hyperlactatemia in human or animal patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0066] introduction

[0067] Induction of marked hyperlactatemia (i.e., 8 to 10 mmol / L) can protect the body from the deleterious effects of hypoglycemia. The state of hypoglycemia and hyperlactatemia combined (HG-HL) is metabolically possible, as highlighted by observations in several disease states in humans (Oldenbeuving et al., Anaesth Intensive Care 2014; 42 :507-11). In animals and humans, syndromes often involving liver failure can be characterized by HG-HL status. Since the HG-HL state as extreme HG (0.7mmol / L)-HL (25mmol / L) has been observed in combination with intact consciousness, this specific state is called lactate-protected hypoglycemia (LPH). LPH may be much more important than mere scientific curiosity, as tumors showing the Warburg effect may be particularly susceptible to low glucose levels, and cancers may not be able to utilize lactate, unlike normal vital tissues in the body . Induction of HG-HL for four hours would profoundly and immediately alter th...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

This invention relates to a kit comprising the components lactic acid, insulin and glucose, and optionally one or more components selected from a glucagon inhibitor, an alpha-beta adrenergic blocker and an antidiabetic agent, for treating a glycolysis-dependent pathological condition in a human or animal. The treatment comprises intravascular, in particular intravenous, delivery of the components lactic acid, insulin and glucose into the circulation of the human or animal to be treated to induce hypoglycemia and hyperlactatemia. The glycolysis-dependent pathological condition is selected from the group consisting of cancer, bacterial infection or parasite infection.

Description

technical field [0001] The present invention relates to a kit comprising various components for the treatment of glycolysis-dependent pathological conditions in humans or animals. Background technique [0002] Cancer is the leading cause of death worldwide and its incidence is increasing, killing more than 8 million people in 2015. Globally, nearly one in six deaths is due to cancer. There are many different forms of cancer, as well as various forms of treatment such as surgery, chemotherapy, radiation therapy, hormone therapy, immunotherapy and other forms of targeted therapy. Many forms of cancer cannot be cured, and not all therapies are equally successful in all patients, so there is still a great need for new treatment modalities. [0003] The present invention is aimed at directly interfering with the metabolism of cancer cells and cancerous tissues. Normal tissues may intermittently produce large amounts of lactate through glycolysis under stressed aerobic conditio...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/28A61K31/191A61K31/7004A61P33/00A61P35/00
CPCA61K31/191A61K31/7004A61K38/28A61P33/00A61P35/00Y02A50/30A61K2300/00A61K9/0019A61K31/155A61K45/06
Inventor 雅各布·坎平加马丁·威廉·尼古拉斯·尼伊斯滕安东尼奥·玛丽亚·佩森蒂阿尔贝托·扎内拉
Owner LACA MEDICAL BV